These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 36692205)

  • 21. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
    Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
    Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of H3 K27M-mutant gliomas in adults.
    Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
    Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Automated Determination of the H3 K27-Altered Status in Spinal Cord Diffuse Midline Glioma by Radiomics Based on T2-Weighted MR Images.
    Li J; Wang Y; Weng J; Qu L; Wu M; Guo M; Sun J; Hu G; Gong X; Liu X; Duan Y; Zhuo Z; Jia W; Liu Y
    AJNR Am J Neuroradiol; 2023 Dec; 44(12):1464-1470. PubMed ID: 38081676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Editorial for "Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging".
    Bonacchi R; De Meo E
    J Magn Reson Imaging; 2023 Sep; 58(3):862-863. PubMed ID: 36661197
    [No Abstract]   [Full Text] [Related]  

  • 25. Exploring MRI Characteristics of Brain Diffuse Midline Gliomas With the H3 K27M Mutation Using Radiomics.
    Li Q; Dong F; Jiang B; Zhang M
    Front Oncol; 2021; 11():646267. PubMed ID: 34109112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
    J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
    Low JT; Wang SH; B Peters K
    CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffuse midline gliomas with histone H3-K27M mutation: A rare case with PNET-like appearance and neuropil-like islands.
    Gao Y; Feng YY; Yu JH; Li QC; Qiu XS; Wang EH
    Neuropathology; 2018 Apr; 38(2):165-170. PubMed ID: 28880421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tectal Low-Grade Glioma with H3 K27M Mutation.
    Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
    World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse midline glioma H3 K27M-mutant in adults: A report of six cases and literature review.
    Alzoubi H; Maraqa B; Hasasna N; Giangaspero F; Antonelli M; Gianno F; Arcella A; Al-Hussaini M
    Clin Neuropathol; 2021; 40(2):108-117. PubMed ID: 33191898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of H3.3 K27M Mutation on Prognosis and Survival of Grade IV Spinal Cord Glioma on the Basis of New 2016 World Health Organization Classification of the Central Nervous System.
    Yi S; Choi S; Shin DA; Kim DS; Choi J; Ha Y; Kim KN; Suh CO; Chang JH; Kim SH; Yoon DH
    Neurosurgery; 2019 May; 84(5):1072-1081. PubMed ID: 29718432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct MRI characteristics of spinal cord diffuse midline glioma, H3 K27-altered in comparison to spinal cord glioma without H3 K27-alteration and demyelination disorder.
    Ying Y; Liu X; Li X; Mei N; Ruan Z; Lu Y; Yin B
    Acta Radiol; 2024 Mar; 65(3):284-293. PubMed ID: 38115811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
    Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
    World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High frequency of H3 K27M mutations in adult midline gliomas.
    Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
    Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
    Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An adult case of diffuse midline glioma with H3 K27M mutation.
    Tu JH; Piao YS; Lu DH; Wang LM; Liu L; Bai DY; Han HW; Lin YK; Zhong S
    Neuropathology; 2020 Dec; 40(6):627-631. PubMed ID: 32954563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma.
    Peng Y; Ren Y; Huang B; Tang J; Jv Y; Mao Q; Liu Y; Lei Y; Zhang Y
    Sci Rep; 2023 Jun; 13(1):9970. PubMed ID: 37340065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
    Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ
    Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.